Company Market Research Report: Berlin-Chemie AG
Company Overview
- Name: Berlin-Chemie AG
- Mission: The mission of Berlin-Chemie is encapsulated in their belief in bettering the quality of life for patients through innovative healthcare solutions, focusing on improving patient health and expanding healthcare access.
- Founded: Berlin-Chemie was founded in 1890. Since 1992, it has been a subsidiary of the Menarini Group.
- Founders: Specific founders' details are not provided.
- Key People: Dr. Stefano Papa - recently appointed to the board for Technical Operations.
- Headquarters: Glienicker Weg 125, 12489 Berlin, Germany.
- Number of Employees: Approximately 5,000 within Berlin-Chemie AG.
- Revenue: €1.469 billion.
- Industry Reputation: Berlin-Chemie is known for developing, producing, and distributing pharmaceutical products, focusing mainly on respiratory products, diabetes, cardiology, and others in Germany, Central and Eastern Europe, as well as the CIS region.
Products
Pharmaceuticals
- Atemwegserkrankungen (Respiratory Diseases): Offers products for the treatment of respiratory ailments.
- Diabetes: Range of medication aimed at managing diabetes.
- Herzkreislauf (Cardiovascular): Products for cardiovascular health management.
- Hauterkrankungen (Skin Conditions): Provides treatments for various skin conditions.
- Schilddrüsenerkrankungen (Thyroid Disorders): Medications targeting thyroid health.
- Gicht (Gout): Treatments for managing and alleviating gout symptoms.
Consumer Healthcare
- Schmerzbehandlung (Pain Treatment): Offers pain treatment solutions addressing different types and severity of pain.
- Magen-Darm-Beschwerden (Gastrointestinal Issues): Provides remedies for stomach and gastrointestinal discomfort.
- Fieber und Erkältung (Fever and Cold): Products specifically designed for fever and cold symptoms.
Notable Products
- ADENURIC®: Tablets used for specific treatment modes, available in various dosages.
- Benalapril®: An array of dosages and combinations focusing on heart-related health.
- Bretaris® Genuair®: Inhalation powders for respiratory issues.
- Espumisan®: Range of products aimed at relieving bloating and gas discomfort.
Recent Developments
- Key Personnel Changes: On January 6, 2025, Dr. Stefano Papa was appointed as a board member, focusing on Technical Operations, further strengthening the company's operational leadership.
- Partnerships: In October 2024, Berlin-Chemie entered a partnership with the football club 1. FC Union Berlin, signifying a strategic alignment between two significant institutions in Berlin.
- Innovation and Research Collaborations: Continued investment in drug development and expansion of diagnostics technology, notably through Menarini Group's broader initiatives at international levels.
- Expanded Licensing and Agreements: On December 5, 2024, A. Menarini Diagnostics announced a distribution agreement with Sinocare for a new glucose monitoring system, showcasing an extension in diagnostic solution offerings.
This research report provides a snapshot of Berlin-Chemie AG, detailing its establishment, current market position, products, and recent strategic initiatives within the competitive pharmaceutical industry landscape.
